Manuscripts should be submitted in Word, use a normal, plain font (12-point Times New Roman), double spacing, margins 2.5 cm from all four sides, italics for emphasis, page numbers included at bottom, uniformly American English. Use the automatic page numbering function to number the pages for first submission to reviewer.
- Title page: This section should start on a new page should provide: a concise and informative title of the article; list the full names; institutional addresses; email addresses for all authors and indicate the corresponding author and a running head of not more than 80 characters.
- Abstract: This part of the manuscript should not exceed 300 words should state concisely the purpose and pertinent methods of the study, as well as the findings and specific conclusions (without title head, background, method or result)
- Keywords: Author(s) must give about 5-8 key words as index terms representing the article content which can identify the most important subjects covered by the paper. They must be placed at the end of the abstract. Do not repeat words used in the title.
Body of Manuscript: should begin on a new page and not exceed 6000 words excluded the references and be arranged as follows:
- Introduction: Include a summary of a search of the literature to indicate why this study was necessary and what it aimed to contribute to the field and relating the manuscript to similar previous research.
- Materials and Methods: This section must contain specific details about the design of the study, materials involved, instruments used, specialized chemical source and the type of analysis used, including a power calculation if appropriate. For studies involving human participants a statement detailing ethical approval and consent should be included in the methods section.
- Results: Should be clear and concise and included statistical analysis with short informative subsections.
- Discussion: The interpreted results should be explained clearly and should relate them to the existing knowledge in the field as clearly as possible.
- Competing interests: Authors are required to complete a declaration of competing interests. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.
- List of abbreviations: For standard abbreviations, authors should follow the guidelines in the Council of Biology Editors Style Manual, 5th edition. All other abbreviations should be defined when first used and listed in a footnote; Abbreviations PDF.
- Acknowledgements: List those individuals who provided help during the research and do not meet the criteria for authorship (e.g., providing language help, writing assistance or proof reading the article etc.).
References: must be restricted to directly relevant published works, usually the total number of references should not exceed 55. AJBM follow the style adopted by the American Medical Association, which, in turn, is based on the style developed by the International Committee of Medical Journal Editors in 1978 in Vancouver. All references must be numbered consecutively and citations of references in text should be identified using Arabic numbers in square brackets before the punctuation mark. (e.g., “as study by Jonh ”. The citations in the reference list should include all named authors, up to the first 3 before adding 'et al.' The reference number should follow the following format:
– Reference to a journal publication:
Rosenau C, Emery D, Keyboard B, Qoronfleh MW. Development of a high-throughput plate-based chemiluminescent transcription factor assay. J Biomol Screen 2004; 9: 334–42.
– Article within a book:
Wentz I, Colby VT, Carrington CB. Infiltrative lung disease. In: Thurlbeck WM, ed. Pathology of the Lung. New York: Thieme Medical Publishers, 1988.
– Newspaper article:
Tynan T. Medical improvements lower homicide rate: study sees drop in assault rate. The Washington Post. 2002 Aug 12;Sect. A:2 (col. 4).
– Conference paper:
programming. ASCO 2012: Role of IL32 in esophageal cancer
– Unpublished material:
Kim H, Philip N, Meashil E. Role of TLR4 in myocardial injury throuh NF-kB pathway. Proc Natl Acad Sci U S A. In press 2004.